Mirum Pharmaceuticals, Inc.
MIRM
Rank in Stocks
#3280
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Share Price
$82.58
Last synced: 2026-10-19
Market Cap
$5.36B
Change (1 day)
3.05%
Change (1 year)
13.08%
Country
US
Trade Mirum Pharmaceuticals, Inc. (MIRM)
Category
Healthcare
Earnings for Mirum Pharmaceuticals, Inc. (MIRM)
Earnings in Jun 2026 TTM: $-857.54M
According to Mirum Pharmaceuticals, Inc. latest financial reports the company's current earnings are $-857.54M. In 2023 the company made an earning of $-162.42M, a decrease compared to its 2022 earnings that were of $-142.07M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Mirum Pharmaceuticals, Inc. from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-857.54M | 886.67% |
| 2024 | $-86.91M | -46.49% |
| 2023 | $-162.42M | 14.33% |
| 2022 | $-142.07M | 69.23% |
| 2021 | $-83.95M | -18.70% |
| 2020 | $-103.26M | 96.57% |
| 2019 | $-52.53M | 202.81% |
| 2018 | $-17.35M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -715.12% |
US
|
|
| $-3.09B | 259.98% |
US
|
|
| $-4.02B | 368.34% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -327.47% |
NL
|
